A Phase II, Multi-Center, Open-Label, Trial of PR104 in Treatment Naive and Sensitive-relapse Small Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2012
At a glance
- Drugs PR 104 (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 01 Mar 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 22 Sep 2008 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 26 Jun 2008 Additional trial identifier 2008-001 reported by Barbara Ann Karmanos Cancer Institute.